146 related articles for article (PubMed ID: 11432619)
1. Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine.
Di Raimondo F; Giustolisi R; Lerner S; Cacciola E; O'Brien S; Kantarjian H; Keating MJ
Ann Oncol; 2001 May; 12(5):621-5. PubMed ID: 11432619
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia.
Hallek M; Langenmayer I; Nerl C; Knauf W; Dietzfelbinger H; Adorf D; Ostwald M; Busch R; Kuhn-Hallek I; Thiel E; Emmerich B
Blood; 1999 Mar; 93(5):1732-7. PubMed ID: 10029603
[TBL] [Abstract][Full Text] [Related]
3. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma.
Hallek M; Wanders L; Ostwald M; Busch R; Senekowitsch R; Stern S; Schick HD; Kuhn-Hallek I; Emmerich B
Leuk Lymphoma; 1996 Aug; 22(5-6):439-47. PubMed ID: 8882957
[TBL] [Abstract][Full Text] [Related]
4. Infections in patients with chronic lymphocytic leukemia treated with fludarabine.
Anaissie EJ; Kontoyiannis DP; O'Brien S; Kantarjian H; Robertson L; Lerner S; Keating MJ
Ann Intern Med; 1998 Oct; 129(7):559-66. PubMed ID: 9758577
[TBL] [Abstract][Full Text] [Related]
5. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL.
Johnson S; Smith AG; Löffler H; Osby E; Juliusson G; Emmerich B; Wyld PJ; Hiddemann W
Lancet; 1996 May; 347(9013):1432-8. PubMed ID: 8676625
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy.
Keating MJ; O'Brien S; Lerner S; Koller C; Beran M; Robertson LE; Freireich EJ; Estey E; Kantarjian H
Blood; 1998 Aug; 92(4):1165-71. PubMed ID: 9694704
[TBL] [Abstract][Full Text] [Related]
7. Activity of serum thymidine kinase in non-Hodgkin lymphoma: relationship to other prognostic factors.
Hallek M; Emmerich B; Strohmeyer S; Busch R; Reichle A; Senekowitsch R
Klin Wochenschr; 1988 Aug; 66(16):718-23. PubMed ID: 3172680
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of thymidine kinase activity in patients with chronic lymphocytic leukemia.
Stelmach P; Błoński JZ; Wawrzyniak E; Schweiger PE; Wilandt A; Majak PE; Robak T
Postepy Hig Med Dosw (Online); 2016 Dec; 70(0):1321-1330. PubMed ID: 28100842
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
Stilgenbauer S; Zenz T; Winkler D; Bühler A; Schlenk RF; Groner S; Busch R; Hensel M; Dührsen U; Finke J; Dreger P; Jäger U; Lengfelder E; Hohloch K; Söling U; Schlag R; Kneba M; Hallek M; Döhner H;
J Clin Oncol; 2009 Aug; 27(24):3994-4001. PubMed ID: 19597025
[TBL] [Abstract][Full Text] [Related]
10. Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression.
Matthews C; Catherwood MA; Morris TC; Kettle PJ; Drake MB; Gilmore WS; Alexander HD
Eur J Haematol; 2006 Oct; 77(4):309-17. PubMed ID: 16856923
[TBL] [Abstract][Full Text] [Related]
11. [Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases].
Kardum-Skelin I; Planinc-Peraica A; Ostojić Kolonić S; Radić-Kristo D; Milas M; Vrhovac R; Sustercić D; Minigo H; Jaksić B
Acta Med Croatica; 2008 Oct; 62(4):351-64. PubMed ID: 19205412
[TBL] [Abstract][Full Text] [Related]
12. Prognostic features and therapeutical approaches in B-cell chronic lymphocytic leukemia: an update.
Molica S; De Rossi G; Luciani M; Levato D
Haematologica; 1995; 80(2):176-93. PubMed ID: 7628755
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of lymphocyte morphology in patients with advanced chronic lymphocytic leukemia treated with first line therapy of fludarabine + prednisone.
Mauro FR; Gentile M; Mancini F; Giannarelli D; Guarini A; De Propriis MS; Cerretti R; Foa R
Haematologica; 2002 Jun; 87(6):602-8. PubMed ID: 12031916
[TBL] [Abstract][Full Text] [Related]
14. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment.
O'Brien S; Kantarjian H; Beran M; Smith T; Koller C; Estey E; Robertson LE; Lerner S; Keating M
Blood; 1993 Sep; 82(6):1695-700. PubMed ID: 8400226
[TBL] [Abstract][Full Text] [Related]
15. [Lipoprotein lipase and serum thymidine kinase level in chronic lymphocytic leukemia and their correlations with other prognostic factors].
Xu W; Shen QD; Yu H; Qiao C; Wu YJ; Liu Q; Zhu DX; Miao KR; Li JY
Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):8-12. PubMed ID: 19563027
[TBL] [Abstract][Full Text] [Related]
16. Variant Richter's syndrome: a rare case of classical Hodgkin's lymphoma developing in a patient with chronic lymphocytic leukemia treated with fludarabine.
Nemets A; Ben Dor D; Barry T; Ducach A; Blumental R; Ben Alon D; Lugassy G
Leuk Lymphoma; 2003 Dec; 44(12):2151-4. PubMed ID: 14959863
[TBL] [Abstract][Full Text] [Related]
17. Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay.
Bosanquet AG; Johnson SA; Richards SM
Br J Haematol; 1999 Jul; 106(1):71-7. PubMed ID: 10444165
[TBL] [Abstract][Full Text] [Related]
18. Chronic lymphocytic leukemia--correlation of response and survival.
Keating MJ; O'Brien S; Robertson L; Huh Y; Kantarjian H; Plunkett W
Leuk Lymphoma; 1993; 11 Suppl 2():167-75. PubMed ID: 8124227
[TBL] [Abstract][Full Text] [Related]
19. Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia.
Lanasa MC; Andritsos L; Brown JR; Gabrilove J; Caligaris-Cappio F; Ghia P; Larson RA; Kipps TJ; Leblond V; Milligan DW; Janssens A; Johnson AJ; Heerema NA; Bühler A; Stilgenbauer S; Devin J; Hallek M; Byrd JC; Grever MR
Leuk Res; 2015 May; 39(5):495-500. PubMed ID: 25804339
[TBL] [Abstract][Full Text] [Related]
20. [Experience with fludarabine treatment and review of the literature].
Telek B; Rejtó L; Kiss A; Batár P; Reményi G; Rák K; Udvardy M
Orv Hetil; 2002 Jun; 143(24):1459-65. PubMed ID: 12138643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
